FDA Gives Fast-Track Status to Anadys’ Hepatitis C Drug Candidate

Xconomy San Diego — 

Shares of San Diego’s Anadys Pharmaceuticals (NASDAQ: ANDS) gave up some of the boost they got Tuesday after the company announced the Food and Drug Administration put the biotech’s drug candidate for hepatitis C on fast-track review. Anadys shares fell in early trading today, after gaining almost 20 percent Tuesday. Shares have traded between $1.36 and $3.13 over the past year. The FDA’s fast-track status is usually used for prospective drugs intended to treat serious and life-threatening diseases that lack current treatments.